2-Aminoethyl 2-methylpropanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Aminoethyl 2-methylpropanoate
• 化学式: C₆H₁₃NO₂
• 分子量: 131.17
• InChiKey: CDFRRDDKJCBDIV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• DNP and DNP Prodrug Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental, Traumatic Brain Injury, Concussion, Dry Eye Disease, Hearing Loss and/or Metabolic Diseases
  申请人：Mitochon Pharmaceuticals, LLC

  公开号：US20170252347A1

  公开（公告）日：2017-09-07

  A composition and method of treatment of neuromuscular, neuromuscular degenerative, neurodegenerative, autoimmune, developmental, traumatic, hearing loss related, and/or metabolic diseases, including spinal muscular atrophy (SMA) syndrome (SMA1, SMA2, SMA3, and SMA4, also called Type I, II, III and IV), traumatic brain injury (TBI), concussion, keratoconjunctivitis sicca (Dry Eye Disease), glaucoma, Sjogren's syndrome, rheumatoid arthritis, post-LASIK surgery, anti-depressants use, Wolfram Syndrome, and Wolcott-Rallison syndrome. The composition is selected from the group consisting of 2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP, bipartite 2,3-dinitrophenol, 2,4-dinitrophenol, 2,5-dinitrophenol, 2,6-dinitrophenol, 3,4-dinitrophenol, or 3,5-dinitrophenol (2,3-DNP, 2,4-DNP, 2,5-DNP, 2,6-DNP, 3,4-DNP, or 3,5-DNP) prodrugs; Gemini prodrugs, bioprecursor molecules, and combinations thereof. A dose of the composition for treatment of neurodegenerative diseases may be from about 0.01 mg/kg of body weight to about 50 mg/kg of body weight of the patient in need of treatment. A dose of the composition for treatment of metabolic diseases may be from about 1 mg/70 kg of body weight to about 100 mg/70 kg of body weight of the patient in need of treatment, and a maximum dose per day is about 200 mg/70 kg of body weight of the patient in need of treatment.

  一种治疗神经肌肉、神经肌肉退行性、神经退行性、自身免疫、发育、创伤、与听力损失相关以及/或代谢性疾病的组合物和治疗方法，包括脊髓性肌萎缩（SMA）综合症（SMA1、SMA2、SMA3和SMA4，也称为I型、II型、III型和IV型）、创伤性脑损伤（TBI）、脑震荡、干眼症（干眼病）、青光眼、Sjogren综合症、类风湿性关节炎、LASIK手术后、抗抑郁药物使用、Wolfram综合症和Wolcott-Rallison综合症。该组合物选自包括2,3-DNP、2,4-DNP、2,5-DNP、2,6-DNP、3,4-DNP或3,5-DNP、二元2,3-二硝基苯酚、2,4-二硝基苯酚、2,5-二硝基苯酚、2,6-二硝基苯酚、3,4-二硝基苯酚或3,5-二硝基苯酚（2,3-DNP、2,4-DNP、2,5-DNP、2,6-DNP、3,4-DNP或3,5-DNP）前药；双生子前药、生物前体分子和它们的组合。治疗神经退行性疾病的组合物剂量可为患者体重约0.01毫克/千克至约50毫克/千克。治疗代谢性疾病的组合物剂量可为患者体重约1毫克/70千克至约100毫克/70千克，每日最大剂量约为患者体重约200毫克/70千克。
• [EN] ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF<br/>[FR] INHIBITEURS D'ALK5, CONJUGUÉS ET LEURS UTILISATIONS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2022006340A1

  公开（公告）日：2022-01-06

  ALK5 inhibitor compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. Additionally, compounds incorporated into a conjugate with an antibody construct are described herein.The disclosed compoundsand conjugates are useful, among other things, in the treating of cancer and fibrosis and modulating ALK5.

  本文披露了用于治疗疾病（如癌症）的ALK5抑制剂化合物、结合物和药物组合物。此外，本文还描述了与抗体构造物结合的化合物。所披露的化合物和结合物在治疗癌症和纤维化以及调节ALK5等方面非常有用。
• Melampomagnolide B Derivatives as Antileukemic and Cytotoxic Agents
  申请人：Crooks Peter A.

  公开号：US20120122943A1

  公开（公告）日：2012-05-17

  Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed.

  Melampomagnolide B被披露为一种新的抗白血病倍半萜。制备了一种生物素共轭衍生物来阐明其作用机制。还披露了Melampomagnolide B的前药。
• Method of cleaning surfaces
  申请人：DOW CORNING CORPORATION

  公开号：EP0417971A2

  公开（公告）日：1991-03-20

  This invention relates to a process of cleaning a surface soiled with a staining agent. The method includes the steps of aplying to the soiled surface a highly cross-linked macroporous hydrophobic copolymer which contains a chemical entrapped therein which is a solvent for the staining agent present on the soiled surface, dissolving the staining agent with the solvent, absorbing the staining agent into the solvent entrapped copolymer and removing the copolymer containing the solvent and the dissolved staining agent from the surface.

  本发明涉及一种清洁被染色剂弄脏表面的工艺。该方法包括以下步骤：将一种高度交联的大孔疏水共聚物涂抹在弄脏的表面上，该共聚物中夹带有一种化学物质，它是弄脏表面上存在的染色剂的溶剂；用溶剂溶解染色剂；将染色剂吸收到夹带溶剂的共聚物中；从表面上清除含有溶剂和溶解的染色剂的共聚物。
• Method of making highly adsorptive copolymers
  申请人：DOW CORNING CORPORATION

  公开号：EP0417606A2

  公开（公告）日：1991-03-20

  A precipitation polymerization process for the production of a macroporous crosslinked copolymer in which there is added to a reactor equipped with a stirrer, at least one monounsaturated monomer and at least one polyunsaturated monomer, dissolving an inorganic polymerization reaction initiator in a homogeneous minimum-boiling binary azeotrope including a solvent and water and conducting the polymerization in the azeotrope.

  一种用于生产大孔交联共聚物的沉淀聚合工艺，其中在装有搅拌器的反应器中加入至少一种单不饱和单体和至少一种多不饱和单体，将无机聚合反应引发剂溶解在包括溶剂和水的均相最小沸程二元共沸物中，并在共沸物中进行聚合反应。